A diabetes epidemic is under way. According to the World Health Organization (WHO), an estimated 30m people worldwide had some form of diabetes in 1985; by 2000, the number had increased to 177m. WHO projections suggest that the number of people suffering from the disease will increase to some 370m by 2030.
Diabetes is the name given to a group of chronic diseases caused by inherited and/or acquired deficiency in the production of insulin by the pancreas, or by the ineffectiveness of the insulin produced. Such a deficiency results in increased concentrations of glucose in the blood, which in turn damage many of the body's systems, in particular the blood vessels and nerves.
A report by Research and Markets focuses on 10 key countries, providing coverage of the market in North America, Europe, Japan and Latin America. These countries accounted for 86% of the global market in 2002. The largest market by a huge margin is the US, which, at close to $7bn in 2002, was well over five times larger than the secondranked market, Japan. Although 2002 was a relatively poor year in the US (with little increase in overall sales), the American market has grown rapidly in recent years, to account for 57% of world sales, compared with less than 50% in 1998. In contrast, relatively steady sales increases in Japan and thirdranked Germany have resulted in a loss of market share for these countries, in global terms. This has also happened elsewhere in Europe, such as in France, Italy and Spain. In contrast, the markets in Canada and Mexico have expanded rapidly.
The costs involved in the care and management of diabetes are increasing rapidly. The WHO estimates that, on a global basis, 45% of health budgets is spent on diabetes and diabetesrelated illnesses. As discussed in this report, a person with diabetes incurs medical costs that are two to five times higher than those of a person without diabetes. Diabetes incurs considerable indirect costs due to the number of patients who may not be able to continue working or work as effectively as they could before the onset of their condition. Factoring in such indirect costs, the American Diabetes Association calculated that the total cost of diabetes in the US was $132bn in 2002.
The second largest class, human insulin/analogues, has also shown strong growth, at 14% per year to just over $4bn in 2002, cannibalising sales of animal insulins, the market for which contracted by almost a quarter each year, on a CAGR basis. The animal insulins class is now very small, with global sales of only $50m in 2002. Other drugs for diabetes (Class A10X) showed virtually no movement over the period reviewed in this report, to stand at $266m in 2002.
The diabetes market is concentrated in the hands of six key players, which between them account for threequarters of sales. In 2002, the market was headed by Lilly, with sales of $2bn and a 16% share. Second ranked Takeda made sales of over $1.8bn, to account for almost 15%. This put the increasingly focused Japanese pharmaceutical company just ahead of Novo Nordisk, which is something of a specialist in the diabetes market. The next three companies in the rankings were the major multinationals, GlaxoSmithKline (GSK), Bristol Myers Squibb (BMS) and Aventis.
Key Findings:
- Currently 45% of health budgets is spent on diabetes and diabetes related illness: this expenditure is also forecast to increase rapidly
- In the short term, recentlylaunched oral antidiabetics, as well as fast and longacting insulins, will drive the market
- There is also a rapid increase in the number of children presenting with the disease
- The market formed by such products totalled over $12bn in 2002
- With sales of $7bn, the US is the dominant market, ahead of Japan and Germany
- Six companies account for 75% of global diabetes sales
- In oral antidiabetics, as well as in insulins, marketers of innovative products face increasing competition from lowerpriced generics and, in Europe, parallel imports
The prevalence of diabetes will increase from 177m worldwide to 370m by 2030. But the market faces unprecedented change in terms of:
- Obesity driving market growth
- Intense competition from effective generics such as metformin and the sulphonylureas
- Uncertain performance of glitazones in nonUS markets
- Impact of oral antidiabetics and oral or inhaled insulins
- Development of drugs targeting specific symptoms
- Payees' increasing resistance to rapidly increasing healthcare costs
Comprehensive data which is accessible and easily manipulated allows you to explore the market, evaluate the competition and optimize your performance.
- Detailed profiles of top six manufacturers and the position of diabetes in their portfolios
- Analysis of all main drug classes history, competition, future performance
- Oral antidiabetics, including discussion of individual drug classes
- Insulin assessed in terms of human insulins and analogues, as well as animal insulins
- Over 30 individual drug profiles:clinical data, licensing, analyst comment, lifecycle management
- Compounds in R&D: with drug profiles and analysis
- Impact of patent expiries
- Analysis of key market drivers
- Forecasts for diabetes market in top ten countries to 2012
- Likely performance of oral antidiabetics and insulins
- Analysis of all main drug classes: history, competition, future performance
Plus background information on diabetes:
Epidemiology of diabetes by country, age, sex, ethnicity, type of diabetes with forecasts Disease overview: definitions, classifications, risk factors, diagnosis methods, treatment guides
For more information visit http://www.researchandmarkets.com/reports/c15077
Subscribe